Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19 (September 2022)

A Bhimraj, RL Morgan, AH Shumaker… - Clinical Infectious …, 2024‏ - academic.oup.com
There are many pharmacologic therapies that are being used or considered for treatment of
coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence …

Neutralizing monoclonal antibodies for treatment of COVID-19

PC Taylor, AC Adams, MM Hufford… - Nature Reviews …, 2021‏ - nature.com
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

The first 12 months of COVID-19: a timeline of immunological insights

T Carvalho, F Krammer, A Iwasaki - Nature Reviews Immunology, 2021‏ - nature.com
Since the initial reports of a cluster of pneumonia cases of unidentified origin in Wuhan,
China, in December 2019, the novel coronavirus that causes this disease—severe acute …

[PDF][PDF] COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management

R Ochani, A Asad, F Yasmin, S Shaikh, H Khalid… - Infez Med, 2021‏ - infezmed.it
SUMMARY majority of patients tend to have a mild illness, a minority of patients develop
severe hypoxia requiring hospitalization and mechanical ventilation. Management is mostly …

Convalescent plasma for Covid-19–induced ARDS in mechanically ventilated patients

B Misset, M Piagnerelli, E Hoste… - … England Journal of …, 2023‏ - Mass Medical Soc
Background Passive immunization with plasma collected from convalescent patients has
been regularly used to treat coronavirus disease 2019 (Covid-19). Minimal data are …

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

P Bégin, J Callum, E Jamula, R Cook, NM Heddle… - Nature medicine, 2021‏ - nature.com
The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear.
Although most randomized controlled trials have shown negative results, uncontrolled …

Immunity, endothelial injury and complement-induced coagulopathy in COVID-19

L Perico, A Benigni, F Casiraghi, LFP Ng… - Nature Reviews …, 2021‏ - nature.com
In December 2019, a novel coronavirus was isolated from the respiratory epithelium of
patients with unexplained pneumonia in Wuhan, China. This pathogen, named severe acute …

Early outpatient treatment for Covid-19 with convalescent plasma

DJ Sullivan, KA Gebo, S Shoham… - … England Journal of …, 2022‏ - Mass Medical Soc
Background Polyclonal convalescent plasma may be obtained from donors who have
recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in …

[HTML][HTML] Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

RECOVERY Collaborative Group - Lancet (London, England …, 2021‏ - pmc.ncbi.nlm.nih.gov
Background Many patients with COVID-19 have been treated with plasma containing anti-
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent …

Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19 (April 2020)

A Bhimraj, RL Morgan, AH Shumaker… - Clinical Infectious …, 2024‏ - academic.oup.com
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …